

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2012 (10.05.2012)

(10) International Publication Number
WO 2012/059103 A1

PCT

(51) International Patent Classification:
C07D 489/12 (2006.01) **C07D 489/08** (2006.01)

(21) International Application Number:
PCT/DK2011/000128

(22) International Filing Date:
4 November 2011 (04.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/410,405 5 November 2010 (05.11.2010) US
PA 2010 01007 5 November 2010 (05.11.2010) DK
PA 2011 00396 25 May 2011 (25.05.2011) DK
61/489,701 25 May 2011 (25.05.2011) US

(71) Applicant (for all designated States except US): **H. LUNDBECK A/S** [DK/DK]; Ottiliavej 9, DK-2500 Valby (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DE FAVERI, Carla** [IT/IT]; Via dei Colli, 28, I-31010 Farra di Soligo (IT). **HUBER, Florian, Anton, Martin** [AT/IT]; Via G.B. Vellutti 34, I-30031 Dolo (IT). **STIVANELLO, Mariano** [IT/IT]; Via Marostica, 20, I-36015 Schio (IT).

(74) Common Representative: **H. LUNDBECK A/S**; Ottiliavej 9, DK-2500 Valby (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD FOR THE MANUFACTURING OF NALTREXONE

(57) Abstract: The present invention relates to an improved process for producing naltrexone [17- (cyclopropylmethyl)-4,5 α -epoxy-3,14-dihydroxy-morphinan-6-one] from noroxymorphone [4,5- α -epoxy-3,14-dihydroxy-morphinan-6-one] by alkylation with a cyclopropylmethyl halide.



WO 2012/059103 A1

METHOD FOR THE MANUFACTURING OF NALTREXONE

Field of the invention

The present invention relates to an improved process for producing naltrexone [17-(cyclopropylmethyl)-4,5 α -epoxy-3,14-dihydroxy-morphinan-6-one] from noroxymorphone [4,5- α -epoxy-3,14-dihydroxy-morphinan-6-one] by alkylation with a cyclopropylmethyl halide.

Background of the invention

Nalmefene is a known opioid receptor antagonist which can inhibit pharmacological effects of both administered opioid agonists and endogenous agonists derived from the opioid system. The clinical usefulness of nalmefene as antagonist comes from its ability to promptly (and selectively) reverse the effects of these opioid agonists, including the frequently observed depressions in the central nervous system and the respiratory system.

Nalmefene has primarily been developed as the hydrochloride salt for use in the management of alcohol dependency, where it has shown good effect in doses of 10 to 40 mg taken when the patient experiences a craving for alcohol (Karhuvaara et al., *Alcohol. Clin. Exp. Res.*, (2007), Vol. 31 No. 7. pp 1179-1187). Additionally, nalmefene has also been investigated for the treatment of other addictions such as pathological gambling and addiction to shopping. In testing the drug in these developmental programs, nalmefene has been used, for example, in the form of a parenteral solution (RevexTM).

Nalmefene is an opiate derivative quite similar in structure to the opiate antagonist naltrexone. Advantages of nalmefene compared to naltrexone include longer half-life, greater oral bioavailability and no observed liver toxicity.

Nalmefene can be produced from naltrexone by the Wittig reaction. Methods for preparation of nalmefene from naltrexone by the Wittig reaction has been described by Hanh et al., (*J. Med. Chem.*, 18, 259-262(1975), Mallinckrodt (US 4,751,307), Meltzner et al., (US patent No. 4,535,157) and by H. Lundbeck (WO 2010/136039). By using the above-mentioned methods, the free base of nalmefene is obtained, which subsequently can be converted into the hydrochloride salt by use of conventional methods.

Naltrexone can be produced from noroxymorphone by various direct and indirect alkylation methods. One method is by direct alkylation of noroxymorphone with cyclopropylmethylbromide. This process has been disclosed in general terms by Rice in WO 91/05768.


Sanofi-Avensis (WO 2008/034973) describes a process for obtaining naltrexone in 88.6% yield by reacting noroxymorphone hydrochloride with cyclopropylmethylbromide in dimethylacetamide in the presence of sodium hydrogen carbonate. Cilag (WO 2008/138605) describes N-alkylation of noroxymorphone with cyclopropylmethylbromide in N-methylpyrrolidone in the presence of sodium hydrogen carbonate. Mallinckrodt (WO 2010/039209) describes N-alkylation of noroxymorphone with cyclopropylmethylbromide in the presence of a protic solvent. Specific examples in WO 2010/039209 describe the addition of water, isopropanol or ethanol as the protic solvent.

There is a need within the field to improve the method of producing highly pure naltrexone and/or to find alternative processes for producing naltrexone. In particular, there is a need for a method that is readily applicable on industrial scale.

Summary of the invention

The present invention relates to an improved process for producing naltrexone [17-(cyclopropylmethyl)-4,5 α -epoxy-3,14-dihydroxy-morphinan-6-one] from noroxymorphone [4,5- α -epoxy-3,14-dihydroxy-morphinan-6-one] by alkylation of noroxymorphone with a cyclopropylmethyl halide in N-ethyl-2-pyrrolidone as depicted in scheme 1 below.

Scheme 1



X is chosen from Br, Cl and I

In one embodiment, naltrexone obtained from the process of the invention is further processed e.g. by the Wittig reaction to nalme-fene.

In one embodiment, the invention relates to a process for the manufacturing of nalme-fene comprising the steps, i) manufacturing of naltrexone by a process of the invention, ii) further processing of naltrexone obtained from i) to nalme-fene optionally by the Wittig reaction.

In one embodiment, the invention relates to naltrexone directly obtained by a process of the invention.

In one embodiment, the invention relates to nalmeferone obtained from naltrexone, wherein said naltrexone is directly obtained by the process of the invention.

5 In one embodiment, the invention relates to a pharmaceutical composition comprising nalmeferone obtained from naltrexone, wherein said naltrexone is directly obtained by the process of the invention.

Definitions

10 Throughout the description, the terms "naltrexone" and "nalmeferone" are intended to include any forms of the compounds, such as the free base and pharmaceutically acceptable salts. The free base and pharmaceutically acceptable salts include anhydrous forms and solvated forms such as hydrates. The anhydrous forms and the solvates include amorphous and crystalline forms. In a particular embodiment naltrexone is in the form of the free base. In a
15 particular embodiment nalmeferone is in the form of the hydrochloride.

In the present context, examples of "cyclopropylmethyl halides" include cyclopropylmethyl bromide, cyclopropylmethyl chloride, cyclopropylmethyl iodide. In a particular embodiment, the term "cyclopropylmethyl halide" refers to cyclopropylmethyl bromide.

In the present context, a "non-protic solvent" refers to any non-protic solvent. Non-
20 limiting examples of non-protic solvents include hydrocarbons, ketones, esters and ethers. In a particular embodiment, the term "non-protic solvent" refers to toluene.

In the present context, an "acid scavenger" refers to a compound selected from organic and inorganic bases, and combinations hereof. Examples include borate salts, phosphate salts, bicarbonate salts (such as KHCO_3 , NaHCO_3 , LiHCO_3 and the like), carbonate
25 salts (such as K_2CO_3 , Na_2CO_3 , Li_2CO_3 and the like), organic bases (such as pyridine, triethylamine, tripropylamine, tributylamine, N,N-diisopropylethylamine, N-methylmorpholine, N,N-dimethylaminopyridine), and mixtures of any of the above. In a particular embodiment, the term "acid scavenger" refers to KHCO_3 . In another particular embodiment, the term "acid scavenger" refers to N,N-diisopropylethylamine.

30 In the present context, the term "chemically pure" has its normal meaning within the art. Accordingly, an obtained compound which is at least 98% chemically pure comprises at

most 2% chemical impurities. The chemical purity may be determined e.g. by HPLC. In the present context chemical purity is determined by % HPLC area.

Detailed description of the invention

5 The inventors have found an improved process for producing naltrexone [17-(cyclopropylmethyl)-4,5 α -epoxy-3,14-dihydroxy-morphinan-6-one] from noroxymorphone [4,5- α -epoxy-3,14-dihydroxy-morphinan-6-one] by alkylation with a cyclopropylmethyl halide in N-ethyl-2-pyrrolidone. The inventors have found that when running the alkylation in N-ethyl-2-pyrrolidone the reaction kinetics can be controlled efficiently and naltrexone is obtained as a
10 chemically pure compound in a high yield.

 In brief, noroxymorphone is mixed with cyclopropylmethyl halide in N-ethyl-2-pyrrolidone. In a preferred embodiment, the reaction is conducted in presence of an acid scavenger. The mixture is heated to a temperature in the range of 30 to 100°C, preferably in the range of 50-70°C, such as in the range of 50-60°C. Reaction time is adjusted in order to
15 have a reasonably high conversion. Optionally, further cyclopropyl methyl halide is added to the mixture and optionally, the mixture is further heated to increase the conversion.

 The formed naltrexone is isolated by a method comprising the following steps

- a) mixing the reaction mixture with an acid
- b) concentrating the reaction mixture
- 20 c) mixing the resulting mixture with water
- d) optionally mixing the reaction mixture with an acid
- e) optionally treating the mixture with charcoal
- f) mixing the resulting mixture with a base
- g) isolating the resulting solid.
- 25 h) optionally suspending the solid in water, mixing with acid followed by mixing with base and then isolating the resulting solid.
- i) drying the solid.

 In one embodiment, prior to the reaction with cyclopropylmethyl halide; noroxymorphone is mixed with N-ethyl-2-pyrrolidone and a non-protic solvent whereupon the mixture of
30 noroxymorphone, N-ethyl-2-pyrrolidinone and non-protic solvent is concentrated for example by distillation under vacuum.

The process of the present invention consistently gives pure naltrexone. The main impurity coming from alkylation of the hydroxyl group in the phenolic moiety is controlled with the process of the invention. The level of the impurity 3-cyclopropylmethylnaltrexone in the isolated naltrexone is below about 0.5% (by area) as measured by HPLC. The process of the invention also allows efficient removal of potentially unreacted noroxymorphone in isolated naltrexone.

Naltrexone prepared according to the method described in this invention can thus be directly used in the preparation of nalme-fene e.g. by Wittig reaction. It is also envisaged in the present invention that such obtained nalme-fene can be transformed into a suitable pharmaceutically acceptable salt form such as the hydrochloride salt. In a particular embodiment nalme-fene hydrochloride is obtained as dihydrate form.

The present invention also relates to a pharmaceutical composition comprising nalme-fene obtained from naltrexone obtained by the process of the invention. The pharmaceutical composition may further comprise at least one pharmaceutically acceptable excipient, carrier and/or diluent, and may be in a solid dosage form, such as a tablet, for oral administration.

Methods for the preparation of solid pharmaceutical preparations are well known in the art. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott Williams & Wilkins (2005). Solid preparations, such as tablets, may be prepared by mixing the active ingredients with an ordinary carrier, such as an adjuvant and/or diluent, and subsequently compressing the mixture in a tableting machine. Non-limiting examples of adjuvants and/or diluents include: corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other appropriate adjuvant or additive such as colourings, aroma, and preservatives may also be used provided that they are compatible with the active ingredients. The pharmaceutical compositions of the invention thus typically comprise an effective amount of nalme-fene hydrochloride and one or more pharmaceutically acceptable carriers.

Nalme-fene hydrochloride obtained according to the present invention may be administered in any suitable way, e.g. orally or parenterally, and it may be presented in any suitable form for such administration, e.g. in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection. In one embodiment, the pharmaceutical composition will comprise nalme-fene in a therapeutically effective amount. The term "therapeutically effective amount" refers to the amount/dose of a compound or pharmaceutical composition that is sufficient to produce an effective response (i.e., a biological or medical response of a tissue, sys-

tem, animal or human sought by a researcher, veterinarian, medical doctor or other clinician) upon administration to a patient. The "therapeutically effective amount" will vary depending on, inter alia, the disease and its severity, and on the age, weight, physical condition and responsiveness of the patient to be treated. Furthermore, the "therapeutically effective amount" may vary if the compound of the invention is combined with one or more compounds: In such a case the amount of a given compound might be lower, such as a sub-effective amount. Preferably, the amount of nalmefene hydrochloride in a pharmaceutical composition in unit dosage form is amount from about 10 mg to about 100 mg, such as from about 10 mg to about 60 mg, e.g. from about 10 mg to about 40 mg, or about 20 mg.

In one embodiment, nalmefene hydrochloride obtained according to the present invention constitutes an active ingredient in tablets, wherein said tablets further comprises lactose anhydrous, crospovidone, microcrystalline cellulose, magnesium stearate and Opadry OY-S-28849.

In an exemplary embodiment, nalmefene hydrochloride obtained according to the present invention constitutes an active ingredient in tablets with the composition of Table 1.

Table 1: nalmefene tablet composition, exemplary embodiment

Content	Quantity
Nalmefene HCl dihydrate	21.9 mg (~20 mg Nalmefene HCl)
Lactose Anhydrous	60.7 mg
Crospovidone	4.5 mg
Microcrystalline Cellulose	61.4 mg
Magnesium Stearate	1.5 mg
Total Core	150 mg
Opadry OY-S-28849 White, consisting of: Hypromellose (5 mPa.S) Macrogol 400 Titanium dioxide (E171)	4.5 mg
Water, purified	q.s.
Total film coated	154.5 mg
Magnesium stearate	q.s.

In particular, it is envisaged that a pharmaceutical composition of the present invention may be used for reduction of alcohol consumption in patients with alcohol dependence. In one embodiment, a composition comprising nalmefene HCl obtained by the present method may be used for the manufacture of a medicament for reduction of alcohol consumption in

5 patients with alcohol dependence.

In another embodiment, the invention relates to a method for treating alcohol dependency, comprising administering a therapeutically effective amount of nalmefene HCl obtained by the present method, or a pharmaceutical composition thereof, to a patient in the need thereof.

10 The term "alcohol dependency" is a commonly known term for a skilled person. In the revised 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IVTR) (*Diagnostic and Statistical Manual of Mental Disorders*, 4th edition text revision, American Psychiatric Publishing, 2000), the term "alcohol dependency" is defined as the presence of three or more of the seven areas of life impairment related to alcohol in the same 12-month

15 period. These impairments include tolerance, evidence of a withdrawal syndrome when alcohol is discontinued or intake is decreased, potential interference with life functioning associated with spending a great deal of time using alcohol, and returning to use despite evidence of physical or psychological problems.

20 All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law), regardless of any separately provided incorporation of particular documents made elsewhere herein.

25 The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. For example, the phrase "the compound" is to be understood as referring to various "compounds" of the invention or particular described aspect, unless otherwise indicated.

30 The description herein of any aspect or aspect of the invention using terms such as "comprising", "having," "including" or "containing" with reference to an element or elements is intended to provide support for a similar aspect or aspect of the invention that "consists of",

“consists essentially of” or “substantially comprises” that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).

- 5 It should be understood that the various aspects, embodiments, implementations and features of the invention mentioned herein may be claimed separately, or in any combination.

Embodiments according to the invention

- 10 In the following, embodiments of the invention are disclosed. The first embodiment is denoted E1, the second embodiment is denoted E2 and so forth.

- E1. A process for the manufacturing of naltrexone, comprising reacting noroxymorphone with cyclopropylmethyl halide in the presence of N-ethyl-2-pyrrolidone.
- 15 E2. The process according to embodiment 1, wherein the reaction takes place in the presence of an acid scavenger.
- E3. The process according to embodiment 2, wherein the acid scavenger is an inorganic or organic base or a mixture thereof.
- 20 E4. The process according to any of embodiments 2-3, wherein the acid scavenger is N,N-diisopropylethylamine.
- E5. The process according to any of embodiments 2-3, wherein the acid scavenger is potassium bicarbonate.
- 25 E6. The process according to any of embodiments 1-5, wherein the cyclopropylmethyl halide is cyclopropylmethyl bromide.
- 30 E7. The process according to any of embodiments 1-6, wherein the reaction takes place in the presence of a non-protic solvent.

- 5
- E8. The process according to any of embodiments 1-7, wherein; prior to the reaction with cyclopropylmethyl halide; noroxymorphone is mixed with N-ethyl-2-pyrrolidone and a non-protic solvent whereupon the mixture of noroxymorphone, N-ethyl-2-pyrrolidinone and non-protic solvent is concentrated.
- E9. The process according to embodiment 8, wherein said mixture of noroxymorphone, N-ethyl-2-pyrrolidinone and non-protic solvent is concentrated by distillation under vacuum.
- 10 E10. The process according to any of embodiments 7-9, wherein the non-protic solvent is toluene.
- E11. The process according to any of embodiments 1-10, wherein N-ethyl-2-pyrrolidone is used in a weight by weight ratio of 0.5:1 to 10:1 in respect to noroxymorphone.
- 15 E12. The process according to embodiment 11, wherein N-ethyl-2-pyrrolidone is used in a weight by weight ratio of 1:1 to 5:1 with respect to noroxymorphone.
- E13. The process according to embodiment 12, wherein N-ethyl-2-pyrrolidone is used in a weight by weight ratio of about 3:1 with respect to noroxymorphone.
- 20 E14. The process according to any of embodiments 1-13, wherein the molar relationship between noroxymorphone and acid scavenger is from about 1:0.5 to about 1:2.
- 25 E15. The process according to embodiment 14, wherein the molar relationship between noroxymorphone and acid scavenger is from about 1:1 to about 1:2.
- E16. The process according to embodiment 15, wherein the molar relationship between noroxymorphone and acid scavenger is from about 1:1 to about 1:1.5.

30

- E17. The process according to any of embodiments 1-16, wherein the molar relationship between noroxymorphone and cyclopropylmethyl halide is from about 1:1 to about 1:2.
- 5 E18. The process according to embodiment 17, wherein the molar relationship between noroxymorphone and cyclopropylmethyl halide is from about 1:1 to about 1:1.5.
- E19. The process according to any of embodiments 1-18, wherein the reaction temperature is in the range of about 30-100°C.
- 10 E20. The process according to embodiment 19, wherein the reaction temperature is in the range of about 50-70°C, such as in the range of 50-55°C or 55-60°C or 60-65°C or 65-70°C.
- 15 E21. The process according to any of embodiments 19-20, wherein the reaction temperature is in the range of about 50-60°C.
- E22. The process according to any of embodiments 1-21, wherein the reaction is running for at least 8 hours; such as in the range of 8-48 hours, such as 8-12 hours, 12-16 hours, 16-20 hours, 20-24 hours, 24-28 hours, 28-32 hours, 32-36 hours, 36-40 hours, 40-44 hours or 44-48 hours.
- 20
- E23. The process according to embodiment 22, wherein the reaction is running for a range of about 12-24 hours.
- 25 E24. The process according to embodiment 23, wherein the reaction is running for a range of about 16-20 hours.
- E25. The process according to any of embodiments 1-24, wherein the formed naltrexone is isolated by a method comprising the following steps
- 30 a) mixing the reaction mixture with an acid
b) concentrating the reaction mixture

- 5 c) mixing the resulting mixture with water
d) optionally mixing the reaction mixture with an acid
e) optionally treating the mixture with charcoal
f) mixing the resulting mixture with a base
g) isolating the resulting solid.
h) optionally suspending the solid in water, mixing with acid followed by mixing with base and then isolating the resulting solid.
i) drying the solid.
- 10 E26. The process according to embodiment 25 wherein the acid in steps a), d) and h) is hydrochloric acid.
- E27. The process according to any of embodiments 25-26, wherein the base in steps f) and h) is ammonium hydroxide.
- 15 E28. The process according to any of embodiments 1-27, wherein the formation of 3-cyclopropylmethyl-naltrexone is less than about 0.5% (by area).
- E29. The process according to any of embodiments 1-28, wherein noroxymorphone is used as starting material in form of its free base or its hydrochloride salt.
- 20 E30. The process according to any of embodiments 1-29, wherein naltrexone is obtained as the free base.
- 25 E31. The process according to embodiment 30, wherein naltrexone free base is obtained as a hydrate.
- E32. The process according to embodiment 31, wherein the naltrexone free base hydrate is a monohydrate.
- 30 E33. The process according to embodiment 32, wherein the naltrexone free base monohydrate is obtained in crystalline form.

- E34. The process according to any of embodiments 1-33, wherein the naltrexone obtained from the process is further processed to give nalmeferene.
- 5 E35. The process according to embodiment 34, wherein naltrexone obtained from the process is further processed by the Wittig reaction to give nalmeferene.
- E36. A process for the manufacturing of nalmeferene comprising the steps
- 10 i) manufacturing of naltrexone by a process according to any of embodiments 1-33
- ii) further processing of naltrexone obtained from i) to nalmeferene optionally by the Wittig reaction.
- E37. The process according to embodiment 36 comprising the following subsequent steps
- 15 iii) precipitating nalmeferene as a pharmaceutically acceptable salt
- iv) optionally purifying the obtained nalmeferene salt.
- E38. The process according to any of embodiments 34-37, wherein nalmeferene is obtained as the hydrochloride.
- 20 E39. The process according to embodiment 38, wherein nalmeferene hydrochloride is obtained as the dihydrate.
- E40. The process according to embodiment 39, wherein nalmeferene hydrochloride dihydrate is obtained in crystalline form.
- 25 E41. A process for manufacturing of a pharmaceutical composition, wherein the pharmaceutical composition comprises nalmeferene obtained from the process according to any of embodiments 34-40.
- 30 E42. Naltrexone directly obtained from the process according to any of embodiments 1-33.

E43. Nalmefene directly obtained from the process according to any of embodiments 34-40.

5 E44. A pharmaceutical composition comprising nalmefene obtained from the process according to any of embodiments 34-40.

Examples

The invention will be illustrated by the following non-limiting examples.

10

HPLC Chromatographic conditions

Column:..... Zorbax Eclipse XDB, 150 × 4.6 mm, 5 μm or equivalent

Mobile Phase A: Buffer

Mobile Phase B: Acetonitrile

15 Buffer:..... 1.1 g of Sodium Octanesulfonate dissolved in 1 L of water,
pH adjusted to 2.3 with H₃PO₄.

Column Temperature:..... 35°C

Detector:..... UV at 230 nm

Flow:..... 1.2 ml/min

20 Injection volume:..... 20 μl

Time of Analysis: 45 minutes

Table 2: HPLC gradient

Time	Mobile Phase A	Mobile Phase B
0	90	10
45	55	45

25 Example 1:

A mixture of noroxymorphone (52.7 g), N-ethyl-2-pyrrolidone (100 ml) and toluene (100 ml) was concentrated under vacuum at 80°C. The mixture was diluted with toluene (100 ml) and concentrated again. The suspension was diluted with N-ethyl-2-pyrrolidone (50 ml). Potas-

sium bicarbonate (24.4 g) and cyclopropylmethyl bromide (29.3 g) were added and the mixture was heated up to 55°C for 23 hours. The composition of the reaction mixture was checked by HPLC (% by area): naltrexone 97.3%, noroxymorphone 1.4%, 3-cyclopropylmethylnaltrexone 0.4%.

5

Example 2:

Noroxymorphone (51.5 g) in N-ethyl-2-pyrrolidone (168 ml) and toluene (100 ml) was concentrated under vacuum at 80-85°C. Toluene was added (200 ml) and vacuum distillation repeated. Potassium bicarbonate (24.4 g) and cyclopropylmethyl bromide (29.3 g) were added and the mixture was heated up to 60°C and maintained at that temperature for 22 hours. Further cyclopropylmethyl bromide (2.3 g) was charged and stirred at 60°C for five additional hours. The composition of the reaction mixture was checked by HPLC: noroxymorphone 1.5%, naltrexone 97.4% and 3-cyclopropylmethyl naltrexone 0.3%. The reaction mixture was treated with HCl 10% (88.9 g) and concentrated under vacuum. The mixture was cooled and diluted with water (1580 g). Ammonium hydroxide 4% in water was added over 3 hours obtaining a suspension (pH 9.3). The suspension was stirred and then filtered. The solid was washed with water and dried under vacuum at 60°C obtaining 55.9 g of naltrexone. HPLC analysis (% by area): naltrexone 99.0%, noroxymorphone 0.1%, 3-cyclopropylmethyl naltrexone 0.3%.

20

Example 3:

A mixture of noroxymorphone (52.7 g), potassium bicarbonate (24.4 g) and cyclopropylmethyl bromide (30.5 g) in N-ethyl-2-pyrrolidone (150 ml) was heated up 60°C for 17 hours. The composition of the reaction mixture was checked by HPLC (% by area): naltrexone 95.7%, noroxymorphone 2.9%, 3-cyclopropylmethylnaltrexone 0.3%.

25

Example 4:

Noroxymorphone (52.7 g) in N-ethyl-2-pyrrolidone (100 ml) and toluene (100 ml) was concentrated under vacuum. Toluene was added (100 ml) and vacuum distillation repeated two more times. The mixture was diluted with N-ethyl-2-pyrrolidone. Cyclopropylmethyl bromide (30.5 g) and N,N-diisopropylethylamine (29.2 g) were added and the mixture was heated up to 60°C and maintained at that temperature for 17 hours. The composition of the reaction mixture

30

ture was checked by HPLC (% by area): naltrexone 95.0%, noroxymorphone 3.3%, 3-cyclopropylmethyl naltrexone 0.3%.

Example 5:

- 5 A mixture of noroxymorphone (60 Kg, 0.209 Kmol), N-ethyl-2-pyrrolidinone (180 kg), cyclopropylmethyl bromide (36.6 kg) and N,N-diisopropylethylamine (35.1 kg) was heated to 52-57°C for 20 hours and 10 minutes. The mixture was then diluted with a solution prepared by mixing hydrochloric acid 37% (29 kg) and water (79 kg). Low boiling compounds were removed by distillation under vacuum keeping the temperature below 70°C. After cooling to 25-30°C the mixture was further diluted with water (1910 kg). Ammonium hydroxide 4% (199 kg) was then added over three hours till pH=9-10 to precipitate the product. The solid was filtered, washed with water (2×120 kg) and dried under vacuum at 60°C obtaining 68.5 kg of naltrexone (molar yield 93.2%). HPLC analysis (% by area): naltrexone 99.1%, noroxymorphone 0.11%, 3-cyclopropylmethyl naltrexone 0.41%

15 Example 6:

- A mixture of noroxymorphone (60 Kg, 0.209 Kmol), N-ethyl-2-pyrrolidinone (180 kg), cyclopropylmethyl bromide (36.6 kg) and N,N-diisopropylethylamine (35.1 kg) was heated to 52-57°C for 18 hours and 30 min. The mixture was then diluted with a solution prepared by mixing hydrochloric acid 37% (29 kg) and water (79 kg). Low boiling compounds were removed by distillation under vacuum keeping the temperature below 70°C. After cooling to 25-30°C the mixture was further diluted with water (1910 kg). Ammonium hydroxide 4% (199 kg) was then added over three hours till pH=9-10 to precipitate the product. The solid was filtered, washed with water (2x120 kg) and dried under vacuum at 60°C obtaining 69 kg of naltrexone (molar yield 89.7%). HPLC analysis (% by area): naltrexone 99.1%, noroxymorphone 0.09%, 3-cyclopropylmethyl naltrexone 0.41%

Example 7:

- A mixture of noroxymorphone (62 Kg), N-ethyl-2-pyrrolidinone (186 kg), cyclopropylmethyl bromide (37.8 kg) and N,N-diisopropylethylamine (36.2 kg) was heated to 52-57°C for 24 hours and 45 min. The mixture was then diluted with a solution prepared by mixing hydrochloric acid 37% (30 kg) and water (82 kg). Low boiling compounds were removed by distillation under vacuum keeping the temperature below 70°C. After cooling to 25-30°C the mixture was

- further diluted with water (1975 kg). Ammonium hydroxide 4% (206 kg) was then added over three hours till pH=9-10 to precipitate the product. The solid was filtered, washed with water (2x124 kg) and dried under vacuum at 60°C obtaining 71.3 kg of naltrexone (molar yield 89.6%). HPLC analysis (% by area): naltrexone 99.45%, noroxymorphone 0.16%, 3-
- 5 cyclopropylmethylnaltrexone 0.28%

CLAIMS

1. A process for the manufacturing of naltrexone, comprising reacting noroxymorphone with cyclopropylmethyl halide in the presence of N-ethyl-2-pyrrolidone.
- 5 2. The process according to claim 1, wherein the reaction takes place in the presence of an acid scavenger.
3. The process according to claim 2, wherein the acid scavenger is an inorganic or organic base or a mixture thereof.
- 10 4. The process according to any of claims 1-3, wherein the cyclopropylmethyl halide is cyclopropylmethyl bromide.
- 15 5. The process according to any of claims 1-4, wherein; prior to the reaction with cyclopropylmethyl halide; noroxymorphone is mixed with N-ethyl-2-pyrrolidone and a non-protic solvent whereupon the mixture of noroxymorphone, N-ethyl-2-pyrrolidinone and non-protic solvent is concentrated.
- 20 6. The process according to any of claims 1-5, wherein N-ethyl-2-pyrrolidone is used in a weight by weight ratio of 0.5:1 to 10:1 with respect to noroxymorphone.
7. The process according to any of claims 1-6, wherein the molar relationship between noroxymorphone and acid scavenger is from about 1:0.5 to about 1:2.
- 25 8. The process according to any of claims 1-7, wherein the molar relationship between noroxymorphone and cyclopropylmethyl halide is from about 1:1 to about 1:2.
9. The process according to any of claims 1-8, wherein the reaction temperature is in the range of about 30-100°C.
- 30 10. The process according to claim 9, wherein the reaction temperature is in the range of about 50-70°C, such as in the range of 50-55°C or 55-60°C or 60-65°C or 65-70°C.

11. The process according to any of claims 1-10, wherein the formed naltrexone is iso-
5 lated by a method comprising the following steps
- a) mixing the reaction mixture with an acid
 - b) concentrating the reaction mixture
 - c) mixing the resulting mixture with water
 - d) optionally mixing the reaction mixture with an acid
 - 10 e) optionally treating the mixture with charcoal
 - f) mixing the resulting mixture with a base
 - g) isolating the resulting solid.
 - h) optionally suspending the solid in water, mixing with acid followed by mixing
 with base and then isolating the resulting solid.
 - 15 i) drying the solid.
12. A process for the manufacturing of nalmeferene comprising the steps
- i) manufacturing of naltrexone by a process according to any of claims 1-11
 - ii) further processing of naltrexone obtained from i) to nalmeferene optionally by the
20 Wittig reaction.
13. The process according to claim 12 comprising the following subsequent steps
- iii) precipitating nalmeferene as a pharmaceutically acceptable salt
 - iv) optionally purifying the obtained nalmeferene salt.
 - 25
14. Naltrexone directly obtained from the process according to any of claims 1-11.
15. Nalmeferene directly obtained from the process according to any of claims 12-13.

INTERNATIONAL SEARCH REPORT

International application No

PCT/DK2011/000128

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D489/12 C07D489/08
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2010/039209 A2 (MALLINCKRODT INC [US]; WANG PETER X [US]; JIANG TAO [US]; BERBERICH DA) 8 April 2010 (2010-04-08) cited in the application	14
A	paragraph [0028]; claim 7; examples 1-12	1-11
X	WO 91/05768 A1 (US HEALTH [US]) 2 May 1991 (1991-05-02) cited in the application	14,15
A	Chart 3	1-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 December 2011

Date of mailing of the international search report

21/12/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Gregoire, Ariane

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/DK2011/000128

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010039209	A2	08-04-2010	
		AU 2009300379 A1	08-04-2010
		CA 2738246 A1	08-04-2010
		CN 102227433 A	26-10-2011
		EP 2344506 A2	20-07-2011
		US 2010081819 A1	01-04-2010
		WO 2010039209 A2	08-04-2010

WO 9105768	A1	02-05-1991	
		AT 178329 T	15-04-1999
		AU 642447 B2	21-10-1993
		CA 2067200 A1	17-04-1991
		DE 69033035 D1	06-05-1999
		DE 69033035 T2	05-08-1999
		DK 0496830 T3	11-10-1999
		EP 0496830 A1	05-08-1992
		ES 2129395 T3	16-06-1999
		GR 3030101 T3	30-07-1999
		JP 2694156 B2	24-12-1997
		JP H04504861 A	27-08-1992
		WO 9105768 A1	02-05-1991
